Foreign Stocks & Emerging Markets

Sanofi: One of the World's Greatest Stocks

Our search for great stocks from around the world led us to the French drug maker.

We went looking for the greatest companies outside the U.S. and came up with eight proven picks. Here's one of them: Sanofi (symbol SNY). To make the list, the businesses had to have U.S.-traded shares and be industry leaders. They also had to possess substantial financial resources to weather rough economic times. Finally, we sought companies that had significant catalysts to drive the next phase of their growth.

Read more about the case for investing in Sanofi below. Prices and related figures for U.S.-traded shares are as of August 23. Earnings estimates are for calendar 2016 and 2017, unless otherwise noted. Price-earnings ratios are based on estimated 2016 earnings, unless otherwise indicated. Also, take a look at seven more great stocks from around the world.

Sanofi

Headquarters: Paris, FranceShare price: $39.05Market capitalization: $100.5 billionEstimated earnings per share: 2016, $3.10; 2017, $3.05Price-earnings ratio: 13P/E ratio on 2017 estimate: 13Dividend yield: 4.3%

The business: Sanofi ranks among the world's biggest drug companies. Its $39.4 billion in 2015 sales make it larger than U.S. giants Eli Lilly (LLY) and Bristol-Myers Squibb (BMY) combined. The 43-year-old company is a major name in drugs for diabetes, cancer and rare diseases. It also produces vaccines for illnesses such as typhoid and dengue, and it owns biotech firm Genzyme.

Track record: Like many of its drug-titan peers, Sanofi has suffered in recent years from rising competition from cheaper generic drugs and from new treatments. That has hurt Sanofi's biggest seller, the long-acting insulin Lantus. Rising sales of new Sanofi drugs for multiple sclerosis and rare diseases have partly offset other declines. But overall the firm's sales and profit have been stagnant for five years. The stock has dropped 17% over the past 12 months, back to 2012 levels, and that has pushed up the dividend yield to a hefty 4.3%.

Reasons to own it: Sanofi is aiming to reignite growth. In November 2015, it detailed plans to boost research spending, cut other costs and refocus some businesses. The company also highlighted the potential market hits already in its pipeline, with 18 new drugs or other products scheduled to be launched between now and 2020. Research firm Morningstar says strong sales in emerging nations, particularly of vaccines, are a major long-term plus. Sanofi also is sharply boosting its presence in over-the-counter consumer products (such as painkillers and cold treatments) by acquiring the consumer arm of German drug giant Boehringer Ingelheim. "Our long-term conviction in the pipeline as well as continued strength from vaccines, consumer and rare disease businesses further strengthens our confidence" in Sanofi's appeal, Morningstar says. For patient investors, this is a chance to buy low.

Most Popular

4 Big Retirement Blunders (and How to Avoid Them)
retirement

4 Big Retirement Blunders (and How to Avoid Them)

It’s too bad, but financial advisers see these four mistakes all the time. Don’t fall into the same traps.
October 6, 2021
13 States That Tax Social Security Benefits
social security

13 States That Tax Social Security Benefits

You may have dreamed of a tax-free retirement, but if you live in these 13 states, your Social Security benefits are subject to a state tax. That's on…
October 4, 2021
How Big of a Threat Does Inflation Pose to Your Retirement?
retirement

How Big of a Threat Does Inflation Pose to Your Retirement?

You might be surprised how much inflation can nibble away at your retirement nest egg over time if you aren’t prepared.
October 3, 2021

Recommended

The Pros and Cons of Target Date Funds with Tony Drake
Financial Planning

The Pros and Cons of Target Date Funds with Tony Drake

The simplicity of target date funds has made them popular, particularly among 401(k) savers. But investors may be paying a price.
October 19, 2021
Robo-Advisers: Weighing the Worth of Automated Advice
investing

Robo-Advisers: Weighing the Worth of Automated Advice

Some people do just fine with bare-bones advice that’s essentially generated by an algorithm. Until your financial life gets more complicated, you mig…
October 17, 2021
Yogi Berra Quotes Investors Can Live By
investing

Yogi Berra Quotes Investors Can Live By

Baseball legend Yogi Berra was wise, in his own muddled way, about more than just sports. His words hold truth in life – and in investing. Here are th…
October 13, 2021
Is Stagflation a Serious Market Risk?
investing

Is Stagflation a Serious Market Risk?

High inflation and corporate warnings of supply chain issues have brought stagflation fretting to a fever pitch.
October 12, 2021